These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35680474)

  • 1. A family cluster of cutaneous Leishmania major infection unresponsive to intralesional meglumine antimonial: Case reports.
    Ziaee M; Ghatee MA; Taylor WR; Karamian M
    Indian J Med Microbiol; 2022; 40(3):451-454. PubMed ID: 35680474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
    Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
    J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
    [No Abstract]   [Full Text] [Related]  

  • 3. Intralesional injections of meglumine antimoniate to treat complex facial leishmania infantum acquired in Spain: a case report.
    Mostmans Y; Van Gysel J; Vanden Nest H; Mervillie K; Richert B; Clevenbergh P
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e548-e550. PubMed ID: 35181939
    [No Abstract]   [Full Text] [Related]  

  • 4. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
    Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
    Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
    J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
    Romero GA; Guerra MV; Paes MG; Macêdo VO
    Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
    Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
    Khatami A; Talaee R; Rahshenas M; Khamesipour A; Mehryan P; Tehrani S; Dowlati Y; Firooz A
    PLoS One; 2013; 8(6):e66123. PubMed ID: 23826087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrocardiographic Alterations Related to Intralesional Glucantime® Treatments: A Potentially Severe Adverse Event.
    García Bracamonte B; Burillo Martínez S; Morales Raya C; Ortiz Romero P
    Actas Dermosifiliogr; 2022; 113(7):742-744. PubMed ID: 35331726
    [No Abstract]   [Full Text] [Related]  

  • 12. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
    Fernández OL; Rosales-Chilama M; Sánchez-Hidalgo A; Gómez P; Rebellón-Sánchez DE; Regli IB; Díaz-Varela M; Tacchini-Cottier F; Saravia NG
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012156. PubMed ID: 38709850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns.
    Aronson NE; Billick K
    Clin Infect Dis; 2023 Aug; 77(4):583-588. PubMed ID: 37185765
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T; Lehn N; Landthaler M; Stolz W
    Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival.
    Gómez MA; Navas A; Márquez R; Rojas LJ; Vargas DA; Blanco VM; Koren R; Zilberstein D; Saravia NG
    J Antimicrob Chemother; 2014 Jan; 69(1):139-49. PubMed ID: 23975742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two small yellowish papules in a 1 year-old boy: cutaneous leishmaniasis.
    Noguera-Morel L; Azorin D; Xirotagaros G
    Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American cutaneous leishmaniasis as a rare imported disease in Europe: a case report favourably treated with antimonial derivatives.
    Manfredi R; di Bari MA; Calza L; Chiodo F
    Eur J Epidemiol; 2001; 17(8):793-5. PubMed ID: 12086100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erysipeloid cutaneous leishmaniasis: about a clinical observation].
    El kartouti A; Elbenaye J; Miloudi M
    Pan Afr Med J; 2015; 21():54. PubMed ID: 26405490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
    Gagini T; de Oliveira Schubach A; de Fatima Madeira M; Maria Valete-Rosalino C; Fernandes Pimentel MI; da Silva Pacheco R
    Parasite; 2017; 24():34. PubMed ID: 28959938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.